Publication: Cross-reactivity of human monoclonal antibodies generated with peripheral blood lymphocytes from dengue patients with Japanese encephalitis virus
1
Issued Date
2013-08-14
Resource Type
ISSN
11775491
11775475
11775475
Other identifier(s)
2-s2.0-84882611859
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Biologics: Targets and Therapy. Vol.7, No.1 (2013), 175-187
Suggested Citation
Chonlatip Pipattanaboon, Tadahiro Sasaki, Mitsuhiro Nishimura, Chayanee Setthapramote, Pannamthip Pitaksajjakul, Pornsawan Leaungwutiwong, Kriengsak Limkittikul, Orapim Puiprom, Mikiko Sasayama, Panjaporn Chaichana, Tamaki Okabayashi, Takeshi Kurosu, Ken ichiro Ono, Pongrama Ramasoota, Kazuyoshi Ikuta Cross-reactivity of human monoclonal antibodies generated with peripheral blood lymphocytes from dengue patients with Japanese encephalitis virus. Biologics: Targets and Therapy. Vol.7, No.1 (2013), 175-187. doi:10.2147/BTT.S47438 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/32208
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Cross-reactivity of human monoclonal antibodies generated with peripheral blood lymphocytes from dengue patients with Japanese encephalitis virus
Abstract
Background: Hybridomas that produce human monoclonal antibodies (HuMAbs) against Dengue virus (DV) had been prepared previously using peripheral blood lymphocytes from patients with DV during the acute and convalescent phases of a secondary infection. Anti-DV envelope glycoprotein (E) 99 clones, anti-DV premembrane protein (prM) 8 clones, and antiDV nonstructural protein 1 (NS1) 4 clones were derived from four acute-phase patients, and anti-DV E 2 clones, anti-DV prM 2 clones, and anti-DV NS1 8 clones were derived from five convalescent-phase patients. Methods and results: In the present study, we examined whether these clones cross-reacted with Japanese encephalitis virus (JEV), which belongs to the same virus family. Forty-six of the above-described 99 (46/99) anti-E, 0/8 anti-prM, and 2/4 anti-NS1 HuMAbs from acutephase, and 0/2 anti-E, 0/2 anti-prM, and 5/8 anti-NS1 HuMAbs from convalescent-phase showed neutralizing activity against JEV. Thus, most of the anti-E and anti-NS1 (but not the anti-prM) antibodies cross-reacted with JEV and neutralized this virus. Interestingly, 3/46 anti-E HuMAbs derived from acute-phase patients and 3/5 anti-NS1 HuMAbs from convalescent-phase patients showed particularly high neutralizing activity against JEV. Consequently, the HuMAbs showing neutralization against JEV mostly consisted of two populations: one was HuMAbs recognizing DV E and showing neutralization activity against all four DV serotypes (complex-type) and the other was HuMAbs recognizing DV NS1 and showing subcomplex-type cross-reaction with DV. Conclusion: Anti-DV E from acute phase (46/99) and anti-DV NS1 (7/12) indicate neutralizing activity against JEV. In particular, three of 46 anti-DV E clones from acute phase and three of five anti-NS1 clones from convalescent phase showed strong neutralizing activity against JEV. © 2013 Pipattanaboon et al, publisher and licensee Dove Medical Press Ltd.